RxSight, Inc. Reports First Quarter 2026 Results and Reiterates Full-Year Sales Outlook

About this update from Rxsight, Inc.

[{"type":"image","alt":"RxSight, Inc.","displaySize":"","headline":null,"caption":"RxSight, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":92,"url":"https://media.zenfs.com/en/globenewswire.com/b21b6ecb1a46af6790a9c276a59298b4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lGQfqXn_sTr0kkp3EBo5ow--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyOQ--/https://media.zenfs.com/en/globenewswire.com/b21b6ecb1a46af6790a9c276a59298b4","width":300,"height":92}},"lazy":false},{"type":"text","content":"ALISO VIEJO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026.","length":153,"tagName":"p"},{"type":"text","content":"Strategic Highlights and Recent Developments","length":44,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Q1 sales of $30.9 million driven by 27,472 Light Adjustable Lens (LAL) units","length":76,"tagName":"p"}]},{"val":[{"type":"text","content":"20 Light Delivery Devices (LDDs) sold in Q1, expanding the installed base to 1,154 units","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"Robust clinical data presented at the recent American Society of Cataract and Refractive Surgery (ASCRS) annual meeting highlighting the versatility and impact of adjustability","length":176,"tagName":"p"}]},{"val":[{"type":"text","content":"Recent regulatory approval in New Zealand furthering the company’s international footprint and global market opportunity","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"2026 sales and gross margin guidance unchanged; operating expense expected to be at high end of previous range reflecting targeted investments in strategic growth initiatives","length":174,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":634,"olType":false},{"type":"text","content":"“We are encouraged by the stabilizing business trends and the initial progress from our ongoing commercial initiatives,” said Ron Kurtz, President and Chief Executive Officer of RxSight. “As we continue to refine these efforts, investing in both our team and our pipeline, we are confident that we can continue to build momentum across the company and reach the full potential of our technology for patients and practices.”","length":423,"tagName":"p"},{"type":"text","content":"First Quarter Financial ...

More updates from Rxsight, Inc.